135 related articles for article (PubMed ID: 27836941)
1. Target-Site Investigation for the Plasma Prolactin Response: Mechanism-Based Pharmacokinetic-Pharmacodynamic Analysis of Risperidone and Paliperidone in the Rat.
Shimizu S; den Hoedt SM; Mangas-Sanjuan V; Cristea S; Geuer JK; van den Berg DJ; Hartman R; Bellanti F; de Lange EC
Drug Metab Dispos; 2017 Feb; 45(2):152-159. PubMed ID: 27836941
[TBL] [Abstract][Full Text] [Related]
2. Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human.
Wong YC; Centanni M; de Lange ECM
J Clin Pharmacol; 2019 May; 59(5):731-747. PubMed ID: 30676661
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.
Kozielska M; Johnson M; Pilla Reddy V; Vermeulen A; Li C; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
Pharm Res; 2012 Jul; 29(7):1932-48. PubMed ID: 22437487
[TBL] [Abstract][Full Text] [Related]
4. Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis.
Paulzen M; Haen E; Stegmann B; Hiemke C; Gründer G; Lammertz SE; Schoretsanitis G
Psychoneuroendocrinology; 2016 Nov; 73():9-15. PubMed ID: 27448523
[TBL] [Abstract][Full Text] [Related]
5. A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats.
Taneja A; Vermeulen A; Huntjens DRH; Danhof M; De Lange ECM; Proost JH
Eur J Pharmacol; 2016 Oct; 789():202-214. PubMed ID: 27395799
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice.
Kirschbaum KM; Henken S; Hiemke C; Schmitt U
Behav Brain Res; 2008 Apr; 188(2):298-303. PubMed ID: 18164477
[TBL] [Abstract][Full Text] [Related]
7. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
[TBL] [Abstract][Full Text] [Related]
8. Development of a non-human primate model to support CNS translational research: Demonstration with D-amphetamine exposure and dopamine response.
Folgering JH; Choi M; Schlumbohm C; van Gaalen MM; Stratford RE
J Neurosci Methods; 2019 Apr; 317():71-81. PubMed ID: 30768951
[TBL] [Abstract][Full Text] [Related]
9. Modeling of prolactin response following dopamine D
Taneja A; Vermeulen A; Huntjens DRH; Danhof M; De Lange ECM; Proost JH
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226628
[TBL] [Abstract][Full Text] [Related]
10. Effect of smoking on risperidone pharmacokinetics - A multifactorial approach to better predict the influence on drug metabolism.
Schoretsanitis G; Haen E; Stegmann B; Hiemke C; Gründer G; Paulzen M
Schizophr Res; 2017 Jul; 185():51-57. PubMed ID: 27993531
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic patterns of risperidone-associated adverse drug reactions.
Schoretsanitis G; Stegmann B; Hiemke C; Gründer G; Schruers KR; Walther S; Lammertz SE; Haen E; Paulzen M
Eur J Clin Pharmacol; 2016 Sep; 72(9):1091-8. PubMed ID: 27376639
[TBL] [Abstract][Full Text] [Related]
12. The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid.
Westerhout J; Smeets J; Danhof M; de Lange EC
J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):327-42. PubMed ID: 23539188
[TBL] [Abstract][Full Text] [Related]
13. Regulation of P-glycoprotein expression in brain capillaries in Huntington's disease and its impact on brain availability of antipsychotic agents risperidone and paliperidone.
Kao YH; Chern Y; Yang HT; Chen HM; Lin CJ
J Cereb Blood Flow Metab; 2016 Aug; 36(8):1412-23. PubMed ID: 26661162
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions.
Paulzen M; Haen E; Gründer G; Lammertz SE; Stegmann B; Schruers KR; Walther S; Schoretsanitis G
J Psychopharmacol; 2016 Aug; 30(8):803-9. PubMed ID: 27251417
[TBL] [Abstract][Full Text] [Related]
15. Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and human.
Ball K; Bouzom F; Scherrmann JM; Walther B; Declèves X
Biopharm Drug Dispos; 2014 Nov; 35(8):485-99. PubMed ID: 25044007
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment.
Schoretsanitis G; Haen E; Gründer G; Stegmann B; Schruers KR; Hiemke C; Lammertz SE; Paulzen M
J Clin Psychopharmacol; 2016 Dec; 36(6):554-561. PubMed ID: 27811552
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic-pharmacodynamic (PopPK/PD) modeling of risperidone and its active metabolite in Chinese schizophrenia patients.
Ji S; Shang D; Wu K; Li A; Li X; Deng C; Li L; Zhou T; Wang C; Lu W
Int J Clin Pharmacol Ther; 2016 May; 54(5):378-89. PubMed ID: 27007997
[TBL] [Abstract][Full Text] [Related]
18. Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.
Vandenberghe F; Guidi M; Choong E; von Gunten A; Conus P; Csajka C; Eap CB
Clin Pharmacokinet; 2015 Dec; 54(12):1259-72. PubMed ID: 26129906
[TBL] [Abstract][Full Text] [Related]
19. In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy.
Loryan I; Melander E; Svensson M; Payan M; König F; Jansson B; Hammarlund-Udenaes M
Mol Psychiatry; 2016 Nov; 21(11):1527-1536. PubMed ID: 26809840
[TBL] [Abstract][Full Text] [Related]
20. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
Olsen CK; Brennum LT; Kreilgaard M
Eur J Pharmacol; 2008 Apr; 584(2-3):318-27. PubMed ID: 18325493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
